Publications

The peer-reviewed record.

Three papers. Every scientific statement on this website traces to them.

  1. Hydralazine induces stress resistance and extends C. elegans lifespan by activating the NRF2/SKN-1 signalling pathway

    Dehghan E, Zhang Y, Saremi B, Yadavali S, Hakimi A, Dehghani M, Goodarzi M, Tu X, Robertson S, Lin R, Chudhuri A, Mirzaei H. Nature Communications 8:2223 (2017).

    doi:10.1038/s41467-017-02394-3 · PMID 29263362 · Read at Nature.com

  2. Hydralazine targets cAMP-dependent protein kinase leading to sirtuin1/5 activation and lifespan extension in C. elegans

    Dehghan E, Goodarzi M, Saremi B, Lin R, Mirzaei H. Nature Communications 10:4905 (2019).

    doi:10.1038/s41467-019-12425-w · PMID 31659167 · Read at Nature.com

  3. Study protocol — not a results paper

    “A randomized clinical trial evaluating Hydralazine’s efficacy in early-stage Alzheimer’s disease: The EHSAN Study”

    Mirzaei M, Ahmadi N, Bagheri Fahraji B, Mellat Ardekani A, Rahimdel A, Soltani MH, Yassini Ardekani SM, Bidaki R, Hosseini Kasnavie F, Dastjerdi G, Aboutorabi M, Mirzaei H. Scientific Reports 14:28837 (2024).

    doi:10.1038/s41598-024-79616-4 · PMID 39572624 · Read at Nature.com

    This article describes the trial’s design and rationale. It does not report the trial’s results, which have not been published. The paper’s title is quoted verbatim; the study enrolled a mild to moderate Alzheimer’s population (MMSE 12–26).

Both Nature Communications papers are open access.